Wednesday, October 31, 2007

Article abstract


Nature Medicine 13, 1228 - 1233 (2007)
Published online: 30 September 2007 | doi:10.1038/nm1664

LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

Sha Mi1,7, Bing Hu2,7,8, Kyungmin Hahm1, Yi Luo1, Edward Sai Kam Hui6, Qiuju Yuan2, Wai Man Wong2, Li Wang2, Huanxing Su2, Tak-Ho Chu2, Jiasong Guo2, Wenming Zhang2, Kwok-Fai So2,3,4, Blake Pepinsky1, Zhaohui Shao1, Christilyn Graff1, Ellen Garber1, Vincent Jung1, Ed Xuekui Wu6 & Wutian Wu2,3,5,7


Demyelinating diseases, such as multiple sclerosis, are characterized by the loss of the myelin sheath around neurons, owing to inflammation and gliosis in the central nervous system (CNS). Current treatments therefore target anti-inflammatory mechanisms to impede or slow disease progression. The identification of a means to enhance axon myelination would present new therapeutic approaches to inhibit and possibly reverse disease progression. Previously, LRR and Ig domain–containing, Nogo receptor–interacting protein (LINGO-1) has been identified as an in vitro and in vivo negative regulator of oligodendrocyte differentiation and myelination. Here we show that loss of LINGO-1 function by Lingo1 gene knockout or by treatment with an antibody antagonist of LINGO-1 function leads to functional recovery from experimental autoimmune encephalomyelitis. This is reflected biologically by improved axonal integrity, as confirmed by magnetic resonance diffusion tensor imaging, and by newly formed myelin sheaths, as determined by electron microscopy. Antagonism of LINGO-1 or its pathway is therefore a promising approach for the treatment of demyelinating diseases of the CNS.Top
  1. Biogen Idec Inc., 14 Cambridge Center, Cambridge, Massachusetts 02142, USA.
  2. Department of Anatomy, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
  3. State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
  4. Research Centre of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
  5. Research Center of Reproduction, Development and Growth, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
  6. Department of Electrical and Electronic Engineering, Faculty of Engineering, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
  7. These authors contributed equally to this manuscript.
  8. Present address: School of Life Science, The University of Science and Technology of China, Hefei, Anhui 230027, China.

Correspondence to: Wutian Wu2,3,5,7 e-mail: wtwu@hkucc.hku.hk

Correspondence to: Sha Mi1,7 e-mail: sha.mi@biogenidec.com


http://www.nature.com/nm/journal/v13/n10/abs/nm1664.html
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

Sha Mi, Bing Hu, Kyungmin Hahm, Yi Luo, Edward Sai Kam Hui, Qiuju Yuan, Wai Man Wong, Li Wang, Huanxing Su, Tak-Ho Chu, Jiasong Guo, Wenming Zhang, Kwok-Fai So, Blake Pepinsky, Zhaohui Shao, Christilyn Graff, Ellen Garber, Vincent Jung, Ed Xuekui Wu, Wutian Wu

Nature Medicine 13, 1228 - 1233 (30 Sep 2007) Article

Tuesday, October 30, 2007

Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? innate - existing in one from birth


Summaries of all the latest research findings on MS selected by a team based at the Institute of Neurology, London.

Migration and multiple sclerosis: The French West Indies experience

This study investigates the incidence of MS in the French west Indies, which has seen a dramatic rise in the condition since large numbers of its population returned from living in France. The authors postulate reduced exposure to sunlight and intestinal parasites as possible reasons.

authors: Cabre P.

source: J Neurol Sci. 2007 Nov 15;262(1-2):117-21. Epub 2007 Jul 24.

read more

Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?

innate - existing in one from birth
This post-mortem study comparing human brain lesions to those in a rat model of MS, found that innate immune cells are active early on in lesion development, before infiltration of the lesion by T-cells (part of the cell-mediated immune process).

authors: Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ.

source: Brain. 2007 Nov;130(Pt 11):2800-15. Links

read more

Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing--remitting experimental autoimmune encephalomyelitis

This study in a mouse model of MS again demonstrates the role of the innate immune cells, this time in grey matter lesions, which have been linked to clinical progression in MS. The study suggests that microglial activation persists through the chronic disease phase, while peak T cell responses are known to be associated with acute inflammation.

authors: Rasmussen S, Wang Y, Kivisäkk P, Bronson RT, Meyer M, Imitola J, Khoury SJ.

source: Brain. 2007 Nov;130(Pt 11):2816-29. Epub 2007 Sep 22.

read more

Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up

In this study of 50 patients with severe RRMS treated with mitoxantrone, one third of patients continued to progress during treatment, although during the follow-up period this number decreased. The patients progressed despite there being no active lesions on their MRI scans. Ten per cent of patients withdrew from treatment due to side effects.

authors: Buttinelli C, Clemenzi A, Borriello G, Denaro F, Pozzilli C, Fieschi C.

source: Eur J Neurol. 2007 Nov;14(11):1281-1287.Links

read more

back to top


No boundaries on anger
Chicago Sun-Times Tue, 30 Oct 2007 2:22 AM PDT
Dear Fixer: On Sept. 26, 2006, I purchased a mobility scooter for my wife because she has multiple sclerosis. The scooter worked fine until July of this year, when it broke down. The FixerNo boundaries on anger

No boundaries on anger

THE FIXER
ON HEALTH | Company that sold scooter has gone out of business -- but their Web site is still up

October 30, 2007

STEPHANIE ZIMMERMANN szimmermann@suntimes.com

Dear Fixer: On Sept. 26, 2006, I purchased a mobility scooter for my wife because she has multiple sclerosis. The scooter worked fine until July of this year, when it broke down.

I contacted No Boundaries Mobility, the seller, since it still was under warranty. They told us to get it fixed, but no one can fix it in our area. We called back but the phone to their office just keeps ringing.

We don't know what to do.

Lenny Heider, Carol Stream

Dear Lenny: We wish we had better news for you, but you may be out of luck -- and out the $2,100 you spent on the scooter. After many frustrating phone calls and database searches, The Fixer tracked down Norman Stein, president of No Boundaries Mobility, who said the company had gone out of business. (Curiously, their Web site is still up -- so customers beware.)

Stein referred us to a guy named Moshe at the Israel-based manufacturer, Tzora Active Systems Ltd.

Moshe, of course, does not return e-mails.

Meanwhile, the Better Business Bureau gives No Boundaries an "F" rating, due to consumers' complaints about defective scooters, difficulties in contacting the company for service and similar problems.

The Fixer is beginning to think there is no boundary on these folks' poor business practices. Sorry -- we wish we had better news.

Getting the runaround over a consumer problem? Tell it to The Fixer at www.suntimes.com. The Fixer on Health deals with medical-consumer issues, not health advice or diagnostical problems
http://www.suntimes.com/news/zimmermann/626295,CST-NWS-FIXER30.article\
__________________________________________________________________
Sangamo shares leap on stem cell tech advance - FierceBiotech - Biotechnology Articles, Biotech Industry News, FDA Approval News

Sangamo shares leap on stem cell tech advance

October 30, 2007

http://www.fiercebiotech.com/story/sangamo-shares-leap-stem-cell-tech-advance/2007-10-30

Shares of Sangamo BioSciences leapt more than 12 percent--to a 52-week high--after researchers published a new study in Nature Biotechnology indicating that its technology could be used to modify the genomes in stem cells. The science could be used to create stem cell lines that mimic disease, a big advance in medical research. Stem cells could also be modified in order to treat disease.

"This is a significant advance for both research and the potential therapeutic use of stem cells," stated Dr. Naldini, a senior author of the study. "Stem cells are the body's natural resource for regeneration and repair and the ability to efficiently add a therapeutic gene into the genome of a cell at a predetermined location or to correct a mutated gene in a patient's stem cells may enable us to provide a long term solution for many genetic diseases."

- see Sangamo's release
- check out the AFX report

Related Articles:
Senate renews battle over stem cell funding. Report
Scientists reprogram mature cells to act embryonic. Report

_____________________________________________________
Summaries of MS news from websites around the world.

New Zealand: 40 years of MSSNZ

While MSIF was celebrating its 40th anniversary in Prague, in New Zealand that same week, the Multiple Sclerosis Society of New Zealand (MSSNZ) was marking its own important 40th anniversary milestone.

read more

France: 2008 €100,000 Scientific Award for MS research from Institut de France

La Fondation NRJ was created in May 1999 to promote medical research, particularly in the neurosciences.

read more

India: MSSI’s Diwali celebrations

On 27 October MSSI (Multiple Sclerosis Society of India) participated in the Diwali Mela at the Italian Embassy, Chanakyapuri. The Mela was a huge success and the MSSI stall sold many lovely things made and contributed by its members Parul, Uma Bhatia, Rani, Anjum, Renuka and Nina, building great awareness for the cause.

read more

Regenerative Medicine for multiple sclerosis

2007 Adult Mesenchymal Stem Cells In Regenerative Medicine ...
The National Center for Regenerative Medicine for Stem Cell and Regenerative ... and neurodegenerative diseases and injuries such as multiple sclerosis. ...

Scientists Find New Causes For Neurodegeneration - By UM Scientists
By Md Moshiur Rahman(Md Moshiur Rahman)
In the normal tissue the cells are tightly packed with no gaps, but in the mutant there are large holes due to loss of neurons from absence of the molecule PI(3,5)P2 from suppression of the Vac14 gene. (Credit: Image courtesy of ...
Today and Tomorrow - http://lhctoday.blogspot.com/

Scientists find new causes for neurodegeneration
By squiffy2
The molecule PI(3,5)P2 is a lipid found in all cells at very low levels. Lipids are a group of small organic compounds. While the best studied lipids are fats, waxes and oils, PI3,5P2 is a member of a unique class of lipids that signal ...
BrainTalk Communities - http://brain.hastypastry.net/forums

Scientists Find New Causes For Neurodegeneration
By Fausto Intilla (fisico teorico)(Fausto Intilla (fisico teorico))
The molecule PI(3,5)P2 is a lipid found in all cells at very low levels. Lipids are a group of small organic compounds. While the best studied lipids are fats, waxes and oils, PI3,5P2 is a member of a unique class of lipids that signal ...
Health & Medicine - News & Press... - http://healthmedicinenewsandpress.blogspot.com/

Multiple Sclerosis Resource Centre Latest MS News
Latest MS News Page providing up to the date breaking Multiple Sclerosis news ... The molecule PI(3,5)P2 is a lipid found in all cells at very low levels. ...

Scientists find new causes for neurodegeneration - BrainTalk ...
The molecule PI(3,5)P2 is a lipid found in all cells at very low levels. ... Squiffy's House of Fun - Laughter for Multiple Sclerosis ...

Scientists discover new causes for neurodegeneration
Weisman said it was surprising to find that PI(3,5)P2 plays a key role in the survival ... The signaling lipid PI(3,5)P2 (short for phosphatidylinositol 3 ...

New Causes For Neurodegeneration Discovered By U-M Scientists ...
The molecule PI(3,5)P2 is a lipid found in all cells at very low levels. ... The signaling lipid PI(3,5)P2 (short for phosphatidylinositol 3,5-bisphosphate) ...

Field,SJ
Interference with PtdIns(4,5)P2 interferes with adhesion of the plasma .... By examining various mutants, we show that synthesis of PI(3,4,5)P3 in S. pombe ...

FirstScience - U-M scientists find new causes for neurodegeneration
The molecule PI(3,5)P2 is a lipid found in all cells at very low levels. Lipids are a group of small organic compounds. While the best studied lipids are ...

New Causes For Neurodegeneration Discovered By U-M Scientists
The signaling lipid PI(3,5)P2 (short for phosphatidylinositol 3 .... Alzheimer's / Dementia · CJD / vCJD / Mad Cow Disease · Multiple Sclerosis ...

Scientists find new causes for neurodegeneration | Huliq
Simple eye scan opens window to multiple sclerosis ... Weisman said it was surprising to find that PI(3,5)P2 plays a key role in the survival of nervous ...

Hiller Amyotrophic Lateral Sclerosis Center - Publications
Mutation of FIG4 encoding a PI(3,5)P2 phosphatase causes neurodegeneration in the pale tremor mouse and in patients with CMT type 4G. ...

Health & Medicine - News & Press (健康與醫學新聞出版)
The molecule PI(3,5)P2 is a lipid found in all cells at very low levels. .... We can insert multiple genes into it to enhance its tumor-killing capabilities ...

Disability Happens » Alzheimer's discovery involves little known lipid
The molecule is PI(3,5)P2 and is a lipid that is found in all cells at very low levels ... Multiple Sclerosis (MS), and Creutzfeldt-Jakob (Mad Cow Disease). ...

Scientists find new causes for neurodegeneration
The molecule PI(3,5)P2 is a lipid found in all cells at very low levels. ... Weisman said it was surprising to find that PI(3,5)P2 plays a key role in the ...

Genzyme Gets It Together
On the R&D front, Genzyme reported positive phase 2 data in multiple sclerosis patients for a formulation of already-marketed leukemia drug Campath. Genzyme and partner Bayer now have the anti-MS version of Campath in two phase 3 studies; if successful, that could put approval somewhere in the 2011 time frame. It's still too early to tell how the drug will fare competitively, though. The strong efficacy data seen thus far has been tempered somewhat with a few moderate safety issues.
http://www.fool.com/investing/high-growth/2007/10/29/genzyme-gets-it-together.aspx
Close Failure for Genzyme
… Unfortunately, with the results that Genzyme (Nasdaq: GENZ) published today for its drug Campath for MS, this appears to be the case. …
www.fool.com/.../2006/09/14/close-failure-for-genzyme.aspx - September 14, 2006

Genzyme Gets It Together
… On the R&D front, Genzyme reported positive phase 2 data in multiple sclerosis patients for a formulation of already-marketed leukemia drug Campath. …
www.fool.com/.../2007/10/29/genzyme-gets-it-together.aspx - October 29, 2007

BEYOND study: Results do not support regulatory filing for ...
PharmaLive.com (press release) - Newtown,PA,USA
Bayer Schering Pharma expects sales of Betaferon® to grow in the range of 7-9 percent in 2007 and 2008. The company's continued investment in lifecycle ...
See all stories on this topic

Positive Development Of BB BIOTECH-share In The 3rd Quarter
ABN Newswire (press release) - Sydney,NSW,Australia
At the same time, the visibility of the sales potential of important drugs such as Biogen Idec's Tysabri or Celgene's Revlimid improved and triggered ...
See all stories on this topic

Teva Third-Quarter Net Falls as US Drug Sales Drop (Update2)
Bloomberg - USA
US regulators decided to allow Elan Corp. and Biogen Idec Inc. to resume sales of their Tysabri MS drug in June 2006. Sales of Tysabri shot up more than ...
See all stories on this topic

Positive development of BB
Ad-Hoc-News (Pressemitteilung) - Germany
Atthe same time, the visibility of the sales potential of importantdrugs such as Biogen Idec's Tysabri or Celgene's Revlimid improvedand triggered ...
See all stories on this topic

_______________________________

Acne Medication May Delay Progress Of Multiple Sclerosis, Canada
Medical News Today (press release) - UK
A common acne medication that has been available for over 30 years has the potential to delay the progress of multiple sclerosis and if proven effective, ...
See all stories on this topic

Acne drug being enlisted to battle MS
Toronto Star - Ontario, Canada
In the five years she's been taking the acne drug minocycline to control her multiple sclerosis, it's the first time the medication has failed her on either ...
See all stories on this topic

Study to probe whether acne drug can slow MS
CTV.ca - Canada
... acne medication could help delay the crippling effects of multiple sclerosis. The medication, called minocycline, has been available for over 30 years. ...
See all stories on this topic

A good pill to swallow for MS?
Canoe.ca (subscription) - Toronto,Ontario,Canada
... the crippling effects of multiple sclerosis. A $4-million clinical trial begins next year to test the effectiveness of the common acne drug minocycline ...
See all stories on this topic

Acne Medication May Delay Progress Of Multiple Sclerosis, Canada
A common acne medication that has been available for over 30 years has the potential to delay the progress of multiple sclerosis and if proven effective, will offer an inexpensive option for the treatment of early MS, says the MS Society of Canada.

______________________________

Monday, October 29, 2007

PI(3,5)P2

Scientists discover new causes for neurodegeneration
News-Medical-Net Sun, 28 Oct 2007 4:18 PM PDT
Diseases that cause neurons to break-down, such as Alzheimer's, Multiple Sclerosis and Creutzfeldt-Jakob disease (Mad Cow Disease), continue to be elusive to scientists and resistant to treatments.

Embryonic stem cells could be ballot issue
The Grand Rapids Press - MLive.com - Grand Rapids,MI,USA
... a difficult question: Should these tiny cell clumps be used to research cures for everything from cancer to multiple sclerosis to Parkinson's disease? ...
See all stories on this topic

Acne medicine could help MS sufferers
Canoe.ca (subscription) - Toronto,Ontario,Canada
A $4 million clinical trial begins next year to test the effectiveness of the acne drug minocycline on 200 early-stage MS patients, said Dr. Luanne Metz, ...
See all stories on this topic

Ireland's Elan sees losses reduced by strong Tysabri sales
Pharma Times (subscription) - London,UK
Net loss decreased 25% to $87.4 million, or $0.19 per share, and revenues reached $176.6 million which benefited from increased take-up of Tysabri ...
See all stories on this topic

Elan's losses narrow on MS drug sales
BusinessWeek - USA
PLC reported lower third-quarter losses Thursday and a sales milestone for its key product, the multiple sclerosis treatment Tysabri. ...
See all stories on this topic

Biogen Idec sale books not out yet, but first round bids expected ...
Financial Times - London,England,UK
The first person familiar noted that decisions pertaining to Tysabri and Rituxan, a drug targeting Non-Hodgkin's Lymphoma which Biogen has a collaborative ...
See all stories on this topic

Elan Corporation narrows Q3 pretax losses to 90.2 mln usd vs 115.6 ...
Forbes - NY,USA
Tysabri is co-marketed with US company Biogen, which has been the object of recent speculation about a possible takeover by US billionaire Carl Icahn. ...
See all stories on this topic

Elan revenues up 43% on Tysabri sales
RTE.ie - Ireland
The increase in revenues was driven mainly by the growing use of its MS drug Tysabri, which generated sales of almost $100m in the three month period. ...
See all stories on this topic

Saturday, October 27, 2007

Researchers uncover clue about multiple sclerosis

KING 5 Seattle Sat, 27 Oct 2007 4:32 PM PDT
A new discovery may help researchers better understand the cause of MS and develop life-saving treatments.

New Causes For Neurodegeneration Discovered By U-M Scientists
Medical News Today Sat, 27 Oct 2007 10:15 AM PDT
Diseases that cause neurons to break-down, such as Alzheimer's, Multiple Sclerosis and Creutzfeldt-Jakob disease (Mad Cow Disease), continue to be elusive to scientists and resistant to treatments.A new finding from University of Michigan researchers demonstrates an unpredicted link between a virtually unknown signaling molecule and neuron health. [click link for full article]

While RA Bids Line Runway, Poll Finds Unhappy Patients
BioWorld Online - Atlanta,GA,USA
In Germany, 4SC AG this month said the last patient was released from the Phase IIa trial with SC12267 for RA, as scheduled. The small molecule DMARD was ...
See all stories on this topic

Friday, October 26, 2007

Nogo in multiple sclerosis: growing roles of a gro...[J Neurol Sci. 2006] - PubMed Result


Department of Immunology, Faculty of Medical Sciences, New University of Lisbon, 1169-056 Lisbon, Portugal. pfontoura@igc.gulbenkian.pt

In recent years, knowledge about the physiological functions of the Nogo-A protein has grown considerably, and this molecule has evolved from being one of the most important axonal regrowth inhibitors present in central nervous system (CNS) myelin, to several other potentially important roles in different areas such as nervous system development, epilepsy, vascular physiology, muscle pathology and CNS tumors. Therapeutically, targeting the Nogo-A protein by means of the immune response has been tried in an attempt to block neurite growth inhibition and promote regeneration in spinal cord injury models; the immune response to Nogo-A, however, has not been extensively studied. We propose to review recent evidence that Nogo-A may also play an important role in autoimmune demyelinating diseases such as experimental autoimmune encephalomyelitis and multiple sclerosis, including that Nogo-66 derived epitopes are encephalitogenic antigens in susceptible mouse strains, and that the immune response to Nogo-66 antigens includes both strong T cell and B cell activation, with epitope spreading of the antibody response to other myelin molecules. In CNS immunotherapy, careful targeting of neural self-antigens is a prerequisite in order to avoid unexpected deleterious effects, and increasing knowledge about the immune response to Nogo-A may provide a safe basis for the development of relevant therapeutic alternatives for several neurological conditions.

PMID: 16682057 [PubMed - indexed for MEDLINE]


http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&uid=16682057&cmd=showdetailview&indexed=google

The Magic of Pumpkin Seeds

October 23, 2007

I'm working on a story today about pumpkin seeds being used to treat people with anxiety. A study was done at Whitby Mental Health Centre that shows they can help decrease anxiety by 16 percent. Here's the catch, you can't just eat them out of the jack o'lantern. The oil in the seed has to pressed out. That way, the tryptophan that is in the seeds can be absorbed into the brain and turned into seratonin. That's in the daytime. At night the brain turns the tryptophan into melatonin which helps you sleep. There are a couple of products in health food stores that have the pumpkin seed flour (with dextrose, which helps absorption as well) I bought some and am going to give it a try. It may help bring down stress level at work and help me sleep through the night.

Let you guys know how it works.


http://www.citynews.ca/blogs/healthydialogue.aspx

Biogen antibody regenerates MS nerves

By Mike Nagle
10/2/2007 - Biogen Idec is pushing forward with a therapeutic antibody that can turn myelin producing cells back on and so could reverse the damaging effects of multiple sclerosis (MS).

Biogen has published the latest preclinical data on its anti-Lingo-1 antibody in this month's issue of Nature Medicine, which suggest the drug can promote myelin production and placement around damaged nerves, at least in animals.


Normally myelin acts a protective cellular sheath around nerve fibres but if it is destroyed, as is the case in MS patients, the cells lose their ability to send signals to the body and can eventually die. This contributes to the disability seen in MS sufferers.

Current MS treatments focus on slowing down this destruction. However, there is no drugs currently available that can repair the damage already done. There are several plausible drug targets being pursued within the pharma industry that could lead to regenerative therapies. On top of Lingo-1, these include Nogo, Notch and Jagged. Stem cell treatment represents a further option that needs investigating further.

Lingo-1 itself appears to be a molecular switch which blocks the ability of cells in the central nervous system to produce myelin. A Lingo-1 antibody effectively 'blocks the blocker' and the end result is that myelin production is restarted.

"While preliminary, these findings are encouraging and suggest that the anti-Lingo-1 antibody has the potential to repair some of the damage caused to the CNS. This may be an entirely new approach to treating MS,"
said Dr Alfred Sandrock, Senior Vice President of Neurology

Research and Development at Biogen.
A disease called experimental autoimmune encephalomyelitis (EAE) is used instead of MS in animal studies to track myelin destruction. If the antibody is introduced before disease onset it can decrease the severity of EAE and can also reduce symptoms if it is given after disease onset, according to Biogen.

Physical improvements in axonal integrity were seen using magnetic resonance DTI imaging, and new myelin sheaths were seen at the cellular level, using histological staining and electron microscopy.

"This....opens the door for the identification of additional regulators of myelin repair that might be used to enhance functional recovery in patients with MS,"
said Dr Robert Miller, who is the Director of the Center for Translational Neuroscience at Case Western Reserve University and also the principal investigator on the study.

Each of this new set of targets represents an exciting possibility for new MS therapies - and other demyelinating diseases, such as leukodystrophies - although it will be several years before one might make it to the market.
http://us-pharmatechnologist.com/news/ng.asp?n=80239-biogen-idec-myelin-multiple-sclerosis-ms-lingo

Database Of Human Genetic Diversity Allows Identification Of ...
Medical News Today (press release) - UK
Daly is an assistant professor of Medicine at Harvard Medical School and a senior associate member of the Broad Institute of Harvard and Massachusetts ...
See all stories on this topic

Biogen antibody regenerates MS nerves
US-PharmaTechnologist.com - London,UK
... of multiple sclerosis (MS). Biogen has published the latest preclinical data on its anti-Lingo-1 antibody in this month's issue of Nature Medicine, ...
See all stories on this topic

KineMed Presents Preclinical Data for Investigational Agent ...
PharmaLive.com (press release) - Newtown,PA,USA
Areas of neurobiology where KineMed has active discovery programs include mood disorders, ALS, multiple sclerosis, Alzheimer's disease, Parkinson's disease, ...
See all stories on this topic


NPR : Stem Cells and Regenerative Medicine in the U.K.
Stem Cells and Regenerative Medicine in the U.K.. Listen to this story. .... It's a similar lesion to a very old multiple sclerosis lesion. ...

NPR : Stem Cells and Regenerative Medicine in the U.K.

Listen to this story...

Talk of the Nation, May 13, 2005 · A long-awaited report of research in which rats with damaged spinal cords were able to regain some use of their limbs was published this week in the peer-reviewed Journal of Neuroscience. However, the study found that the approach does not seem to be applicable to patients with chronic injuries. We'll talk about the work and its implications for rebuilding a damaged nervous system.

Guests:

Professor Dame Julia Polak, director, Tissue Engineering and Regenerative Medicine Centre, Imperial College London

LISTEN
http://www.npr.org/templates/story/story.php?storyId=4651065

Biogen antibody regenerates MS nerves

By Mike Nagle
10/2/2007 - Biogen Idec is pushing forward with a therapeutic antibody that can turn myelin producing cells back on and so could reverse the damaging effects of multiple sclerosis (MS).
Biogen has published the latest preclinical data on its anti-Lingo-1 antibody in this month's issue of Nature Medicine, which suggest the drug can promote myelin production and placement around damaged nerves, at least in animals.
Normally myelin acts a protective cellular sheath around nerve fibres but if it is destroyed, as is the case in MS patients, the cells lose their ability to send signals to the body and can eventually die. This contributes to the disability seen in MS sufferers.
Current MS treatments focus on slowing down this destruction. However, there is no drugs currently available that can repair the damage already done. There are several plausible drug targets being pursued within the pharma industry that could lead to regenerative therapies. On top of Lingo-1, these include Nogo, Notch and Jagged. Stem cell treatment represents a further option that needs investigating further.
Lingo-1 itself appears to be a molecular switch which blocks the ability of cells in the central nervous system to produce myelin. A Lingo-1 antibody effectively 'blocks the blocker' and the end result is that myelin production is restarted.
"While preliminary, these findings are encouraging and suggest that the anti-Lingo-1 antibody has the potential to repair some of the damage caused to the CNS. This may be an entirely new approach to treating MS," said Dr Alfred Sandrock, Senior Vice President of Neurology Research and Development at Biogen.
A disease called experimental autoimmune encephalomyelitis (EAE) is used instead of MS in animal studies to track myelin destruction. If the antibody is introduced before disease onset it can decrease the severity of EAE and can also reduce symptoms if it is given after disease onset, according to Biogen.
Physical improvements in axonal integrity were seen using magnetic resonance DTI imaging, and new myelin sheaths were seen at the cellular level, using histological staining and electron microscopy.
"This....opens the door for the identification of additional regulators of myelin repair that might be used to enhance functional recovery in patients with MS," said Dr Robert Miller, who is the Director of the Center for Translational Neuroscience at Case Western Reserve University and also the principal investigator on the study.
Each of this new set of targets represents an exciting possibility for new MS therapies - and other demyelinating diseases, such as leukodystrophies - although it will be several years before one might make it to the market.
http://us-pharmatechnologist.com/news/ng.asp?n=80239-biogen-idec-myelin-multiple-sclerosis-ms-lingo

Database Of Human Genetic Diversity Allows Identification Of ...
Medical News Today (press release) - UK
Daly is an assistant professor of Medicine at Harvard Medical School and a senior associate member of the Broad Institute of Harvard and Massachusetts ...
See all stories on this topic

Biogen antibody regenerates MS nerves
US-PharmaTechnologist.com - London,UK
... of multiple sclerosis (MS). Biogen has published the latest preclinical data on its anti-Lingo-1 antibody in this month's issue of Nature Medicine, ...
See all stories on this topic

KineMed Presents Preclinical Data for Investigational Agent ...
PharmaLive.com (press release) - Newtown,PA,USA
Areas of neurobiology where KineMed has active discovery programs include mood disorders, ALS, multiple sclerosis, Alzheimer's disease, Parkinson's disease, ...
See all stories on this topic


NPR : Stem Cells and Regenerative Medicine in the U.K.
Stem Cells and Regenerative Medicine in the U.K.. Listen to this story. .... It's a similar lesion to a very old multiple sclerosis lesion. ...

NPR : Stem Cells and Regenerative Medicine in the U.K.

Listen to this story...

Talk of the Nation, May 13, 2005 · A long-awaited report of research in which rats with damaged spinal cords were able to regain some use of their limbs was published this week in the peer-reviewed Journal of Neuroscience. However, the study found that the approach does not seem to be applicable to patients with chronic injuries. We'll talk about the work and its implications for rebuilding a damaged nervous system.

Guests:

Professor Dame Julia Polak, director, Tissue Engineering and Regenerative Medicine Centre, Imperial College London

LISTEN
http://www.npr.org/templates/story/story.php?storyId=4651065

Living Forever, The Longevity Revolution : The Nature of Things with David Suzuki : CBC-TV


Immortality. Life Extension. The Fountain of Youth. Real science or simply wishful thinking? Is it hope or is it hype?
Find out in Living Forever: The Longevity Revolution. Scientists from around the world are racing to answer one of humanity's chief questions: can we turn back the human clock? Hitch a ride on this controversial roller-coaster with charismatic gerontologist Michael Rose as he leads us to where the cutting-edge science in life extension is happening: biotechnology, genetic research, therapeutic cloning and stem-cell research – fields which have moved to the outer reaches of our wildest imagination.

In Living Forever we also meet the “believers” among us: the colourful characters who refuse to succumb to the grim reaper. And let's not forget the specialists who predict whether their clients have what it takes to live past 100.

The Longevity RevolutionJust to be clear, Living Forever is not a documentary about 60-year-olds who want to look like young and sexy 25-year-olds. This is a film about stopping, slowing down – even reversing – human aging. It is about the modern quest to create a longer, healthier old age, or – the Holy Grail – eliminating old age altogether.

So, what happens if humans are able to live for another 100 or 500 years? Should we create a race of immortals, just because we have the know-how? At what evolutionary cost? What about the ethical issues? Given humanity's trajectory thus far, it's likely that most people will say ethics be damned: let The Longevity Revolution begin.

WATCH VIDEO


http://www.cbc.ca/natureofthings/video_player.html?livingforever

http://www.cbc.ca/natureofthings/longevityrevolution.html

Acne medicine could help MS sufferers
Calgary Sun Thu, 25 Oct 2007 1:47 PM PDT
Researchers in Calgary are exploring a promising drug therapy that has the potential to delay the crippling effects of multiple sclerosis — a common acne medication that has been on the market for three decades.
Careers in Neuroscience: From Protons to Poetry
ScienceCareers.org - Washington,DC,USA
To answer questions about complex neurological diseases such as Alzheimer's and multiple sclerosis, one needs biostatisticians, disease experts, ...
See all stories on this topic

Biogen Idec 3Q profit falls 24 pct
BusinessWeek - USA
Tysabri, a newer MS medication, brought $63 million in revenue for Biogen Idec, up from $19 million in last year's third quarter, when the medication had ...
See all stories on this topic

Tysabri, Elan, and a Prayer
Motley Fool - USA
By the end of the quarter, 16000 patients were taking Tysabri commercially, giving Elan and Biogen a $448 million annualized run rate for the compound, ...
See all stories on this topic

Morning business news
RTE.ie - Ireland
News in brief - Revenues at Elan, for the three months to the end of September increased by 43%, driven by the uptake of its MS treatment Tysabri. ...
See all stories on this topic

Multiple Sclerosis Society of Canada: Acne Medication May Delay ...
Market Wire (press release) - USA
Clinical researchers in Calgary and 13 other Canadian centres will be taking an in-depth look at an oral therapy known as minocycline after initial studies ...
See all stories on this topic

Trial to test effectiveness of antibiotic in fighting MS
Vancouver Sun - British Columbia, Canada
... be put to the test in multiple sclerosis (MS) as a $4 million study seeks confirmation that minocycline pills can indeed help stop disease progression. ...
See all stories on this topic

Antibiotic Gives Stroke Victims New Hope
NewsMax.com - West Palm Beach,FL,USA
Minocycline, which is a derivative of tetracycline, has already been shown to have a protective effect in animal models of multiple sclerosis, Parkinson's ...
See all stories on this topic

Multiple Sclerosis Society of Canada: Acne Medication May Delay Progress of Multiple Sclerosis

Canadian researchers investigate common medication as alternative MS treatment

CALGARY, ALBERTA--(Marketwire - Oct. 25, 2007) - A common acne medication that has been available for over 30 years has the potential to delay the progress of multiple sclerosis and if proven effective, will offer an inexpensive option for the treatment of early MS, says the MS Society of Canada.
Clinical researchers in Calgary and 13 other Canadian centres will be taking an in-depth look at an oral therapy known as minocycline after initial studies have shown promising results. A new $4 million multi-centre clinical trial involving 200 participants from across Canada is being funded through the MS Society's related MS Scientific Research Foundation.
"The benefits of minocycline are straight forward: it's relatively cheap, has few side effects and can be taken in pill format, " says Dr. Luanne Metz, principal investigator for the study and a professor of clinical neurosciences at the University of Calgary Faculty of Medicine. "The aim of our research is to see if this common drug can reduce the occurrence of further disease activity in people who have experienced an initial attack of MS symptoms and who are at high risk of progressing to definite MS. Without treatment, two thirds of people facing this circumstance are expected to be diagnosed with MS within 6 months. We believe minocycline can reduce this number."
In MS, myelin, which is the protective coating of the nerve fibres of the brain and spinal cord, becomes inflamed. This inflammation can be seen as characteristic lesions by magnetic resonance imaging (MRI). Previous clinical tests of minocycline have shown an 84 per cent reduction of MS lesion activity on MRI.
"There is obvious benefit in delaying the rate of disease progression in MS, from improved quality of life to reduced healthcare expenses," says Dr. William McIlroy, national medical advisor for the MS Society of Canada. "The breadth of the study, the reputation of the researchers involved and the early clinical data supports the view that there is considerable promise for minocycline. We would not be involved if this were not the case."
Minocycline works by inhibiting the activities of an enzyme and immune cells that are keys to initiating MS attacks. It has been used in acne treatment for its anti-bacterial effects but studies have shown its anti-inflammatory properties could be important factors in slowing down MS. These insights were discovered through pioneering research funded by the MS Society of Canada and led by Dr. V. Wee Yong at the University of Calgary (U of C). Drs. Metz and Yong lead the MS program at the Hotchkiss Brain Institute at U of C where many of the early studies on minocycline took place.
In comparing minocycline to current therapies, the cost savings would be substantial. In generic form, minocycline is available for as low as $800 per year. Current MS therapies can cost between $18,000 and $40,000 per year. Researchers note that minocycline would not necessarily replace current therapies, but might delay the timeframe in which they would be required.
The study will be randomized and double-blind by design. Investigators will compare 100 mg of oral minocycline twice daily to placebo over a period of two years.
Enrolment will begin in early 2008 and 14 MS clinics are involved including institutions in Calgary, Vancouver, Burnaby, Edmonton, Red Deer, Saskatoon, London, Toronto, Kingston, Ottawa, Montreal, Quebec City, Sherbrooke and Halifax.
About the MS Society of Canada
Founded in 1948, the MS Society has a membership of 28,000, with seven regional divisions and nearly 120 chapters. The MS Society provides services for people with MS, family members and caregivers. The MS Society also offers a unique support network for children and teenagers with MS and their parents. The MS Society raises funds to support research and services almost entirely through individual and corporate donations and fundraising events across the country. The MS Society is the single largest funder of MS research in Canada. For more information, visit www.mssociety.ca.

For more information, please contact

Multiple Sclerosis Society of Canada
Stewart Wong
National Manager, Media and Public Relations
(416) 967-3025 or Cell: (416) 575-3025
Website: www.mssociety.ca

Click here to see all recent news from this company

Privacy Statement | Terms of Service | Sitemap |© 2007 Marketwire, Incorporated. All rights reserved.
1-800-774-9473 (US) | 1-888-299-0338 (Canada) | +44-20-7562-6550 (UK)

Thursday, October 25, 2007

Living Forever, The Longevity Revolution : The Nature of Things with David Suzuki : CBC-TV


WATCH VIDEO

Living Forever
Watch an excerpt online.

http://www.cbc.ca/natureofthings/longevityrevolution.html

Wednesday, October 24, 2007

New Test Gene Could Help Treat Multiple Sclerosis
abc7news.com - San Francisco,CA,USA
By Carolyn Johnson Oct. 22, 2007 - KGO - Multiple sclerosis or MS is a frustrating disease to treat. There are drugs to help symptoms, but none that targets ...

http://abclocal.go.com/kgo/story?section=drive_to_discover&id=5721124

Fluoxetine Shows Promise in Multiple Sclerosis

Fluoxetine

Brand name: Prozac

http://www.docguide.com/news/content.nsf/news/852571020057CCF685257378005DF75E

http://www.medscape.com/viewarticle/564301?src=mp

News Author: Thomas S. May
CME Author: Laurie Barclay, MD

Disclosures

The supporter had no role in selecting the study or interview sources for news coverage, and it did not review or approve the news article before publication.

October 16, 2007 (Prague, Czech Republic) — Fluoxetine (Prozac) may help reduce the number of new brain lesions in patients with multiple sclerosis (MS), according to a study presented here at the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

The study, which was conducted by Jop P. Mostert, MD, and colleagues at the University of Groningen, the Netherlands, shows a trend toward a reduction in new enhancing lesions with fluoxetine treatment in patients with relapsing-remitting or relapsing secondary progressive MS.

Why Fluoxetine?

Fluoxetine, a selective serotonin reuptake inhibitor, was approved by the US Food and Drug Administration in 1987 and is frequently prescribed for the treatment of various psychiatric disorders, including major depression. However, fluoxetine also has a number of immunomodulatory effects, and previous studies have indicated that it might be beneficial for patients with MS, Dr. Mostert said in his presentation.

One of these earlier studies, which was first presented at the 1997 Annual Meeting of the American Association of Neurology, showed that fluoxetine reduced disease activity in experimental autoimmune encephalomyelitis, the animal model of MS, Dr. Mostert noted. "Furthermore, psychiatrists already reported in 1991 reduced MS in patients using fluoxetine," he added.

Previous research has also found that astrocytes in patients with MS lack beta-2 adrenergic receptors, and this leads to decreased cyclic adenosine monophosphate (cAMP) production, which in turn contributes to the initiation of the inflammatory cascade that eventually results in demyelination, Dr. Mostert explained. Because fluoxetine is able to increase the amount of cAMP in the astrocyte, the researchers hypothesized that the drug could help compensate for the loss of beta-2 adrenergic receptors and thus, reduce the amount of inflammation in MS.

Fewer New Lesions

To test their hypothesis, Dr. Mostert's team enrolled 40 patients (age 18 - 65 years) with relapsing-remitting or relapsing secondary progressive MS in a randomized, double-blind, placebo-controlled trial, with a duration of 24 weeks. Half of the patients were given fluoxetine (20 mg/day), whereas the remaining subjects received placebo.

The primary end point was the cumulative number of new gadolinium-enhancing lesions on T1-weighted magnetic resonance imaging (MRI) of the brain performed at weeks 4, 8, 16, and 24. Secondary outcome measures included changes in the Expanded Disability Status Scale (EDSS) and in the Multiple Sclerosis Self-Efficacy Scale (MSSE) from baseline to week 24.

The investigators found that the study drug was generally well tolerated, with only 1 patient dropping out because of adverse effects (nausea) in the treatment group. One patient also dropped out from the placebo group, leaving 19 completers in each group.

Regarding the primary end point, the results show that there was a trend toward a reduction in the number of new enhancing lesions in patients treated with fluoxetine. The mean (SD) cumulative number of new enhancing lesions during the 24 weeks of treatment was 1.84 (2.9) in the fluoxetine-treated patients and 5.16 (8.6) in the control subjects (P = .15).

At week 4, the cumulative number of new enhancing lesions was "quite comparable" in the two 2 groups, pointed out Dr. Mostert. He emphasized, however, that in the latter part of the trial, there was a steady increase in new lesions in the placebo group, while the number of lesions in the fluoxetine-treated patients remained relatively stable. Restricting the analysis to the last 16 weeks showed a "nearly significant" reduction in the cumulative number of new enhancing lesions and a higher number of patients without new enhancing lesions (63% vs 26%; P = .02).

Commenting on the study, session cochair Roland Liblau, MD, PhD, from Toulouse University Hospital in France, noted that the researchers used "a very interesting approach," because fluoxetine has a very good safety profile.

"It has been used in hundreds of thousands of patients, so we know it's safe," he told Medscape Neurology and Neurosurgery. "The possibility that it has even a slight effect in multiple sclerosis would be very interesting," he added. "The data showed a trend toward efficacy in MS, and I would strongly encourage further trials involving more patients."

This study was an investigator-initiated trial, with no pharmaceutical industry funding.

Pearls for Practice

  • In a 24-week, randomized, double-blind, placebo-controlled trial of 40 patients with relapsing-remitting or relapsing secondary progressive MS, there was a nonsignificant trend toward a reduction in the number of new enhancing MRI lesions in patients treated with fluoxetine, 20 mg/day. At week 4, the cumulative number of new enhancing lesions was similar in both groups. However, in the last 16 weeks, there was a nearly significant reduction in the cumulative number of new enhancing lesions and a higher number of patients without new enhancing lesions.
  • Fluoxetine was generally well tolerated, and only 1 patient dropped out because of adverse effects (nausea) in the treatment group. One patient also dropped out from the placebo group. Fluoxetine has a very good safety profile.

MS Treatments Ease Life For Patients
WGAL 8 Susquehanna Valley Tue, 23 Oct 2007 11:24 AM PDT
New treatments mean that people with multiple sclerosis can live with fewer restrictions

MS therapy centre faces closure
BBC News Tue, 23 Oct 2007 4:13 AM PDT
A Lincolnshire centre for sufferers of multiple sclerosis could close due to a lack of funding.

Now MS care can come to your door
Belfast Telegraph Tue, 23 Oct 2007 3:24 AM PDT
A new initiative aimed at bringing care and services to Multiple Sclerosis sufferers in rural or remote areas has been launched by a leading MS charity.

(AFX UK Focus) 2007-10-23 14:43 GMT: Teva's Copaxone reduces disease activity in those switching from interferon beta
Interactive Investor Tue, 23 Oct 2007 7:10 AM PDT
NEW YORK (Thomson Financial) - Teva Pharmaceutical Industries Ltd. said Tuesday a study showed its multiple sclerosis drug Copaxone "significantly" decreased disease activity in patients who switched from interferon beta because of the development of neutralizing antibodies.

Biogen realised $63m from Tysabri
RTE.ie - Ireland
US sales were $266m. The company said it recognised $63m from Tysabri, its multiple sclerosis drug which it markets in partnership with Elan.
See all stories on this topic

Elan partner Biogen's Q3 drops 24pc
Irish Independent - Dublin,Ireland
The company said yesterday that revenue from Tysabri, the MS it develops with Elan, was $93m (€65.2m). Biogen's share of the revenue from Tysabri was $63m ...
See all stories on this topic

Antisense Therapeutics to Present at Rodman & Renshaw 9th Annual ...
Trading Markets (press release) - Los Angeles,CA,USA
The Company's current Phase IIa trial is a study in 80 patients to assess the safety and efficacy of ATL1102 as a treatment for relapsing remitting MS. ...
See all stories on this topic

NJ stem cell facility hailed
CNNMoney.com - USA
Many believe stem cell research will bring cures for ailments such as spinal cord injuries, Parkinson's disease, sickle cell anemia and multiple sclerosis. ...
See all stories on this topic

Stopping inflammation opens many avenues for Cognosci
TechJournal South - Research Triangle Park,NC,USA
Stem cell therapy is the only other thing that stimulates rebuilding. “We’re going to start with MS and work our way up the food chain,” says Vitek. ...
See all stories on this topic

Micromet is Presenting Four Posters on BiTE(R) Antibodies at the ...
CNNMoney.com - USA
EpCAM is found widely expressed on human cancers and is also found on so called 'cancer stem cells' from colon, pancreas, prostate and breast tumors. ...
See all stories on this topic

Beating brain cancer
Dailyrecord.com - Parsippany,NJ,USA
I keep taking the Keppra (seizure med) but other than that ... I don't have much else to do until my December MRI. Today is certainly a rainy crappy day ...
See all stories on this topic

Tuesday, October 23, 2007

Immune Ablation and Autologous Stem Cell Transplantation for Aggressive Multiple Sclerosis: Presented at ECTRIMS

By Chris Berrie
PRAGUE, CZECH REPUBLIC -- October 22, 2007 -- Immunoablative therapy plus autologous stem cell transplantation (ASCT) completely abrogates relapses and MRI events related to ongoing inflammation for up to 5 years, researchers reported here at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Mark S. Freedman, MD, Steering Committee Member and Professor of Neurology, University of Ottawa, and Director, Multiple Sclerosis Research Unit, Ottawa Hospital-General Campus, Ottawa, Canada, presented the 5-year interim analysis from a 3-year phase 2 study.
"If we completely remove the diseased immune system, we should halt ongoing immune-mediated damage, because we would have removed the mistake," Dr. Freedman said during his presentation on October 13. Furthermore, the purified stem cells should be capable of restoring a functional immune system, and might even be capable of stimulating repair.
Therefore, Dr. Freedman and colleagues conducted a study to determine if immunoablative therapy and ASCT induces long-lasting MS progression-free responses in patients with active and progressive disease who have a poor prognosis.
They enrolled patients aged 18 to 50 years with active MS with relapses or progression and sustained accumulated impairment. Patients had a high risk of progression, an Expanded Disability Status Scale (EDSS) from 3 to 6, and evidence of current disease activity, and had undergone at least 1 year of other standard MS therapy.
The main steps of the protocol included stem cell mobilization: cyclophosphamide 4.5 g/m2, followed by granulocyte-colony stimulating factor (G-CSF) 10 mcg/kg/day for 10 days; leukophoresis and CD34+ stem cell collection. The immunoablation comprised: busulfan 9.6 mg/kg; cyclophosphamide 200 mg/kg, and rabbit ATG 5 mg/kg; with the ASCT carried out with G-CSF 5 mcg/kg/day.
Due to patient safety considerations (one early death due to busulfan-induced complications), busulfan dosing was later modified from 1 mg/kg/dose every 6 hours for 16 doses to 0.8 (0.6 in future) mg/kg IV for 16 doses, to avoid first pass effects and to minimize liver toxicity, Dr. Freedman noted.
Treatment failure was defined according to any two of the following: significant and sustained EDSS progression; at least two relapses at any time; and Gd+-enhancing lesions on any two consecutive MRI. However, the researchers' original definition of treatment success no longer holds due to difficulties in patient enrolment, particularly into the control arm.
The 25 patients available for evaluation were aged 26 to 41 years, MS duration of 30 to 128 months, had an EDSS score pre-ASCT of 3 to 6.5, and one to five relapses in the previous 2 years.
To date, no patient has experienced any attacks since undergoing ASCT. Although mild EDSS progression has been seen in four patients (one being a control subject, +1/1.5), a further three patients have shown EDSS improvements (-2 to -4), while in the remainder of subjects EDSS scores remained being stable. Dr. Freedman also indicated that the individual patient EDSS progression or improvement appear to be related to EDSS at baseline (progression only with EDSS 5.5 or greater).
For MRI lesions, Dr. Freedman said, "We have been without a single new Gd-enhancing or re-enhancing lesion post-transplantation. In fact, not a single new T2 lesion has developed in any patient since [ASCT]."
Finally, he gave some particular examples of the evidence of specific, but delayed, clinical improvements seen in some of the Kurtzke functional subscores. "This does suggest to us that in the absence of ongoing inflammation, the brain may be capable of some repair, and maybe this had been stimulated by the transplanted autologous bone-marrow-derived stem cells."
Funding for this study was provided by Bayer Schering Pharma AG.
[Presentation title: Immune Ablation and Autologous Stem Cell Transplantation for Aggressive Multiple Sclerosis: Interim 5-Year Report. Abstract 73]
http://www.docguide.com/news/content.nsf/news/852571020057CCF68525737C0071AAAB

Immune Ablation and Autologous Stem Cell Transplantation for ...
DG News - USA
[Presentation title: Immune Ablation and Autologous Stem Cell Transplantation for Aggressive Multiple Sclerosis: Interim 5-Year Report. Abstract 73]
See all stories on this topic

Short-Term Exposure to Cyclophosphamide Reduces Long-Term Brain ...
DG News - USA
... exposure to the potent immunosuppressive effects of cyclophosphamide can prevent brain atrophy in patients with relapsing-remitting multiple sclerosis ...
See all stories on this topic

Elan Q3 loss seen narrowing on higher sales
Therapeutics Daily (subscription) (press release) - Newtown,PA,USA
"We are expecting product revenues to increase 57 percent (year-on-year) primarily reflecting increased sales of Tysabri and contract manufacturing revenues ...
See all stories on this topic

Capacity doubled for fishy pharmaceutical
DrugResearcher.com - London,UK
The company concentrates on developing new lipid compounds that have more specific biological effects than natural polyunsaturated fatty acids, ...
See all stories on this topic

Sunday, October 21, 2007

Research shows monoclonal antibody effective in multiple sclerosis

Thursday, October 18, 2007; Posted: 07:43 AM

http://www.tradingmarkets.com/.site/news/Stock News/715117/
Oct 18, 2007 (Datamonitor via COMTEX) -- ACOR | charts | news | PowerRating -- Researchers at Mayo Clinic have presented details from a preclinical study showing that a recombinant human monoclonal antibody, administered in a single low dose in a laboratory mouse model of multiple sclerosis, can repair myelin, the insulating covering over nerve fibers in the central nervous system.

The antibody, which was genetically engineered for large-scale production, binds to myelin and the surface of cells in the brain and spinal cord, triggering the cells to begin the repair process called remyelination. The study was conducted using a laboratory mouse model of chronic progressive multiple sclerosis in humans. The antibody was delivered alone and in combination with the steroid methylprednisolone, remyelination was detected in both instances. The antibody is being developed by Mayo Clinic and Acorda Therapeutics.

Andrew Blight, chief scientific officer at Acorda, said: "We are excited to be collaborating with Mayo on the development of this therapy. The options for treatment of MS are still quite limited, and a new approach that could repair damage to the central nervous system would represent an important advance for the individuals who live with this disease."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

http://www.tradingmarkets.com/.site/news/Stock%20News/715117/

Research shows monoclonal antibody effective in multiple sclerosis
Trading Markets (press release) - Los Angeles,CA,USA
Oct 18, 2007 (Datamonitor via COMTEX) -- ACOR | charts | news | PowerRating -- Researchers at Mayo Clinic have presented details from a preclinical study ...
See all stories on this topic

Genzyme's Campath Effective in MS
Forbes - NY,USA
AP 10.15.07, 11:00 AM ET Biotechnology company Genzyme Corp. said Monday its leukemia drug Campath was more effective than Merck KGaA's Rebif in treating ...
See all stories on this topic

Fluoxetine for Relapsing Multiple Sclerosis: Presented at ECTRIMS
DG News - USA
The study inclusion patients with confirmed relapsing-remitting (RR) or secondary progressive (SP) MS with exacerbations (one in the last year, ...
See all stories on this topic

Elan Says Has Tysabri Options
Houston Chronicle - United States
2007 AP NEW YORK — Elan Corporation Plc. said Monday it has several options for its share in the multiple sclerosis drug Tysabri if partner Biogen Idec Inc. ...
See all stories on this topic

THE medicine Man
Irish Independent - Dublin,Ireland
Corporate raider Carl Icahn's bid for pharmaceutical firm Biogen also puts Irish drug company Elan, which owns the other 50pc of wonder-drug Tysabri, ...
See all stories on this topic

Biogen bid has secured the survival of Elan
Irish Independent - Dublin,Ireland
Carl Icahn's bid for Biogen -- which jointly owns the MS drug Tysabri with Elan -- has put a floor under the Elan share price and allows investors to look ...
See all stories on this topic

Treosulfan.com - The official site for treosulfan information

Why is this medication prescribed?

Treosulfan is one of a group of anti-cancer medicines called 'alkylating agents', which works by preventing the growth and division of cells and therefore stops them increasing in numbers.

This medication is commonly used as a chemotherapy drug to treat ovarian cancer. Doctors also sometimes use it in high doses to treat people with leukaemia who are going to have a donor bone marrow or stem cell transplant.

Additionally, treosulfan is currently used in clinical trials on patients who desire to try a new treatment approach
http://www.treosulfan.com/

Romney's day of reckoning
Indianapolis Star - United States
He notes, "Romney's wife, Ann, has multiple sclerosis, a neurodegenerative disease that could be helped by stem cells. And Mitt comes out against it. ...
See all stories on this topic

Stem Cell Research Proceeds Apace, But Many Challenges Lie Ahead
BioResearch Online (press release) - Horsham,PA,USA
One effect of this is that when injected into a body, the cells automatically home in on inflamed tissue. In multiple sclerosis, for example, the cells find ...
See all stories on this topic

Insomnia drug falls short in clinical trial

MediciNova said its product MC-305 for the treatment of insomnia didn't achieve statistically significant results in a Phase 2 clinical trial involving 90 patients. The company said it would stop the insomnia trial but try to license the product for development in treating psychiatric disorders.

“As announced in June, we remain focused on advancing two core assets: MN-221 for the treatment of status asthmaticus, for which we recently announced positive Phase 2A data, and MN-166 for the treatment of multiple sclerosis, which also demonstrated positive clinical benefits in the first-year analysis of a two-year Phase 2 clinical trial,” CEO Yuichi Iwaki said.

Shares closed at $7.45 but dropped to $5.40 in after-hours trading.

MS 150 cyclists start first leg
San Antonio Express-News Sat, 20 Oct 2007 8:42 PM PDT
Injured Iraq veterans among riders raising funds for multiple sclerosis.

Saturday, October 20, 2007


Video News DirectorWatch

Garlic Touted As Major Preventative For Serious Diseases

Garlic Touted As Major Preventative For Serious DiseasesThursday October 18, 2007

Garlic. It's not such a great idea on a first date but it's good for you on so many other levels.

That's right. The pungent root goes a long way in fighting everything from cancer to cardiovascular disease.

Recent studies suggest that compounds in garlic cause tissues or blood vessels to release a chemical called hydrogen sulfide that keeps your blood flowing easily.

But, if you have too much of it the effects can be deadly.

Health Specialist Laura DiBattista will have more on this story on an upcoming CityNews at Six. Until, then here are some useful links on the benefits of garlic.

Health benefits and uses

Benefits of garlic in cancer

More useful facts

Culinary uses


http://www.citynews.ca/news/news_15890.aspx